A carregar...
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
BACKGROUND: Rolapitant, a long-acting neurokinin (NK)(1) receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK(1) RAs, rolapitant does not inhibit or induce...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5452074/ https://ncbi.nlm.nih.gov/pubmed/28327932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx073 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|